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Background: The faecal immunochemical test (FIT) is replacing the guaiac faecal occult blood test in colorectal cancer screening.
Increased uptake and FIT positivity will challenge colonoscopy services. We developed a risk prediction model combining routine
screening data with FIT concentration to improve the accuracy of screening referrals.
Methods: Multivariate analysis used complete cases of those with a positive FIT (X20 mgg 1) and diagnostic outcome (n¼ 1810;
549 cancers and advanced adenomas). Logistic regression was used to develop a risk prediction model using the FIT result and
screening data: age, sex and previous screening history. The model was developed further using a feedforward neural network.
Model performance was assessed by discrimination and calibration, and test accuracy was investigated using clinical sensitivity,
specificity and receiver operating characteristic curves.
Results: Discrimination improved from 0.628 with just FIT to 0.659 with the risk-adjusted model (P¼ 0.01). Calibration using the
Hosmer–Lemeshow test was 0.90 for the risk-adjusted model. The sensitivity improved from 30.78% to 33.15% at similar specificity
(FIT threshold of 160 mgg 1). The neural network further improved model performance and test accuracy.
Conclusions: Combining routinely available risk predictors with the FIT improves the clinical sensitivity of the FIT with an increase
in the diagnostic yield of high-risk adenomas.
Colorectal cancer (CRC) is the third most common cancer in men
and the second most common in women (Ferlay et al, 2015). In
England, people aged 60 to 74 years are offered a biennial guaiac
faecal occult blood test (gFOBT) as part of the NHS Bowel Cancer
Screening Programme (BCSP). A newer test, the faecal immuno-
chemical test (FIT), has been shown to have superior analytical
performance and enhanced clinical performance compared with
gFOBT (van Rossum et al, 2008; Allison et al, 2014; Launois et al,
2014).
In England, a 6-month pilot study was initiated by the NHS
BCSP to assess uptake and acceptability, as well as diagnostic
performance (Moss et al, 2016). A marked improvement in uptake
was observed compared with the gFOBT (66.4 vs 59.3%). This
improved uptake, combined with higher positivity, increases
demand on a finite colonoscopy service. A suggested annual
increase of 290 000 additional participants could place impossible
demands on the service (Moss et al, 2016). FIT thresholds between
150 and 180 mg Hb g 1 faeces were considered by the pilot to
ensure demands on colonoscopy were within the available capacity
(Moss and Mathews, 2015; Moss et al, 2016).
Another approach that could improve effective colonoscopy use,
test accuracy and consequently health outcomes is personalised
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risk-based CRC screening (Auge et al, 2014; Cooper et al, 2016;
Moss et al, 2016). A few studies have developed risk prediction
models that combine the FIT concentration with other risk
indicators for use in screening referral decisions (Omata et al, 2011;
Tao et al, 2012; Auge et al, 2014; Stegeman et al, 2014; Yen et al,
2014; Aniwan et al, 2015; Otero-Este´vez et al, 2015). Stegeman et al
(2014) combined FIT with risk factors obtained from a lifestyle
questionnaire in a logistic regression model and found improved
sensitivity at a similar specificity.
Previous studies have required additional testing or lifestyle
questionnaires to obtain predictor information for the model.
Sending additional documents such as questionnaires have been
shown to significantly lower screening uptake (Watson et al, 2013).
A more efficient approach is for the prediction model to utilise
screening data routinely available as an electronic record, thus
reducing participant burden, enhancing data accuracy and
completeness.
Although logistic regression is typically used in medical research
for prediction modelling, other machine learning algorithms such
as artificial neural networks could perform better in certain
medical scenarios (Sargent, 2001; Dreiseitl and Ohno-Machado,
2002). The real advantage of a neural network is in their flexibility
to model complex nonlinear relationships between predictors and
outcome. They can also provide absolute risk probabilities for use
in decision-making.
The aim of this study was to develop a risk prediction model
combining routinely available predictors from the NHS Bowel
Cancer Screening System (BCSS) with individual FIT results to
determine whether model performance and test accuracy are
improved in an average risk English screening population. An
artificial neural network model was also investigated to determine
if this improved predictive power further.
MATERIALS AND METHODS
Since this study develops a risk prediction model and assesses test
accuracy, the Transparent Reporting of a multivariable prediction
model for Individual Prognosis Or Diagnosis (TRIPOD) and
Standards for Reporting of Diagnostic Accuracy Studies (STARD)
statements have been followed when reporting this study (Bossuyt
et al, 2003; Collins et al, 2015).
Study population and data source. The NHS BCSP performed a
comparative study to determine the acceptability and accuracy of
the FIT compared with the gFOBT (Moss et al, 2016). The study
involved two out of the five regional screening hubs in England:
(i) the Midlands and North West Hub and (ii) the Southern Hub.
Between 7 April and 10 October 2014, 1 126 087 individuals were
invited to complete a gFOBT and 40 930 invited to complete a FIT
(1 out of 28 screening invitations). The pilot analysed data from
participants aged 59 to 75 years old and is discussed in further
detail elsewhere (Moss et al, 2016). This analysis is limited to
complete cases (i.e. participants with complete data records) and
those who had a FIT result of X20 mg g 1 (the threshold chosen
for the pilot) and a definitive colonoscopy outcome (n¼ 1810).
The data used for both the FIT pilot and this study were held on
the BCSS, which contains routine information on the screening
pathway for all participants. These data were anonymised and
provided by the Health and Social Care Information Centre
(HSCIC) – now NHS Digital – through the Office for Data Release.
The data were extracted by the HSCIC on the 10 March 2016.
Ethical approval was obtained from the University of Warwick
Biomedical and Scientific Research Ethics Committee (Reference
Number REGO-2015-1575). For the sample population analysed,
FIT kits were distributed between 15 April 2014 and 19 November
2014. Completed kits were received at the lab between 22 April
2014 and 5 March 2015 and examined between 25 April 2014 and
9 March 2015.
Routinely available predictors. The routinely available predictors
recorded on the BCSS that were investigated included age, sex,
Index of Multiple Deprivation (IMD) score and previous screening
history (i.e. whether someone was a previous non-responder/
responder to gFOBT screening compared with a first time invitee
at baseline). Age at the start of the screening episode for the pilot
was provided by NHS Digital. Social deprivation was measured
using the IMD score, which is derived using the English Indices of
Deprivation 2010 based on participant postcode (Department for
Communities and Local Government, 2011).
FIT concentration (Index test). The OC-SENSOR FIT was
measured using the OC-SENSOR Diana analyser (Eiken Chemical
Co. Ltd, Tokyo, Japan, supplied by Mast Diagnostics, Bootle, UK).
The FIT units were converted from ng Hbml 1 buffer to mg
Hb g 1 faeces as recommended by the World Endoscopy
Organisation (Fraser et al, 2012). FIT kits were sent by post for
participants to complete at home and returned by mail to the
screening hubs.
Colonoscopy (diagnostic test). Subjects with a positive test were
offered a specialist screening practitioner appointment within 14
days of a positive FIT test and, if appropriate, referred for a
colonoscopy assessment within 14 days of this appointment
(alternative investigations are arranged if the colonoscopy is
inappropriate, for example, CT scan or flexible sigmoidoscopy)
(Department of Health, 2014). Colonoscopies were performed
using the quality assurance guidelines for colonoscopy published
by the NHS Cancer Screening Programmes (NHS BCSP, 2011).
Model outcome. The binary model outcome was CRC or
advanced adenoma (combined) detected at colonoscopy after a
positive FIT referral. Advanced adenomas were those classified as
either high risk or intermediate risk, as these have potential if left
untreated to develop into CRC (Winawer and Zauber, 2002;
Brenner et al, 2007). An abnormal diagnostic test outcome
indicates that an abnormality has been detected, but not polyps
or cancer (e.g. haemorrhoids). The NHS BCSS uses an algorithm to
record the diagnosis of an individual based on the guidelines for
CRC screening and surveillance (Supplementary Table S1) (Cairns
et al, 2010). Where there was more than one diagnostic outcome
recorded for an individual, the ‘greatest risk’ scenario was used.
Statistical analysis. All data were analysed in RStudio Version
0.99.903 (driven by R version 3.3.1) on a Windows 7 computer (R
Core Team, 2014). Two models were tested using logistic
regression, with a binary response variable of cancer/advanced
adenoma status: (i) FIT concentration only as a predictor and
(ii) FIT concentration and routine data. The risk-adjusted model
(ii) was then extended further using a feed forward neural network.
Routinely available risk predictors recorded on the BCSS were
selected based on previous studies (Auge et al, 2014; Stegeman
et al, 2014) and the information available from the data extract.
The risk-adjusted model was built by adding all the routinely
available risk factors into a single multivariable logistic regression
model and then using backwards elimination to remove non-
significant variables with a P-value 4 0.1. To address overfitting,
10-fold cross-validation was used during model development
(Moons et al, 2015). Cross-validation involves partitioning the data
sample into distinct subsets, performing the analysis on one subset
(training data), and validating the analysis on the other subset
(validation data). All possible pairwise interactions were investi-
gated, none of which were significant at the 5% level.
All continuous variables were kept as such (i.e. not dichot-
omised/categorised) as recommended by the TRIPOD guidelines
(Altman and Royston, 2006; Royston et al, 2006; Moons et al, 2015).
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The log of the FIT concentration was used for analysis. Age was not
formally significant in the model but was retained a priori in a
minimum model due to clinical importance (McDonald et al, 2012;
Auge et al, 2014; Stegeman et al, 2014). Screening history was coded
as a factor (either a previous responder, previous non-responder
compared with first time invitee at baseline). This was determined
using two variables recorded on the BCSS; sequence number and
type of episode.
Model performance was assessed using calibration and dis-
crimination. Calibration (the agreement between observed out-
comes and predictions) was determined using the Hosmer–
Lemeshow statistic and calibration plots of predicted risk vs
observed risk for deciles of participants (Steyerberg, 2009).
Discrimination (the ability of the test to distinguish between those
with and without the outcome) was assessed using the c-statistic
(the area under the receiver operating characteristic (ROC) curve).
The likelihood ratio test was used to determine whether the risk-
based model had a significantly better fit than the model with just
the FIT alone. Overall model performance was assessed using
Nagelkerke’s R2 (Nagelkerke, 1991).
The ROC curves were plotted for the risk-adjusted FIT model
and FIT only to compare test accuracy across different thresholds.
Individuals were then sorted by predicted probability and the
number of referrals kept the same between using the FIT alone and
using risk-adjusted FIT. Two by two tables were produced to
determine the sensitivity and specificity for thresholds between 150
and 180 mg g 1 (and the equivalent risk threshold) for both
models. These thresholds were selected based on previous work
from the FIT pilot (Moss et al, 2016). A threshold of 150 mg g 1
gave a similar positivity rate to the gFOBT and 180 mg g 1 a
similar referral rate (Moss and Mathews, 2015; Moss et al, 2016). A
recommended threshold for the NHS Bowel Cancer Screening
programme based on colonoscopy capacity is B160 mg g 1. It is
anticipated that Wales will adopt a threshold of 150 mg g 1 and
Scotland 80 mg g 1. Results for thresholds between 30 and
180 mg g 1 are presented in the Supplementary Material.
An alternative, and possibly a better performing model to the
conventional logistic regression is a feedforward artificial neural
network (ANN). This model is highly flexible and, unlike logistic
regression, does not require the strong assumption of linearity for
combinations of variables allowing more complex nonlinear
relationships between predictors and the response variable (Tu,
1996). For neural network development, the package ‘nnet’ in R
was used for analysis purposes (Venables, 2002).
A multilayer ANN model with an input layer (consisting of the
same predictors as the logistic regression model), a single hidden
layer and an output layer with a single node was developed (Tu,
1996). Model fitting proceeded in a similar manner to that
described for the logistic regression model using cross-validation,
allowing performance to be compared directly (Steyerberg, 2009).
The continuous variables (including log of FIT) were standardised
using Gaussian normalisation as this approach produced lower
cross-validated deviances. Networks were pruned to improve
generalisation by dropping out weights with the lowest magnitude
and assessing the change in cross-validated deviance (Ripley,
2007). A range of values of the weight decay regularisation term
were also tested to give the lowest SSE (sum of squared errors). The
final optimised neural network model was then compared with the
logistic regression model by assessing model performance and test
accuracy.
RESULTS
Study population. From a total of 40 930 individuals who were
sent a FIT kit, 27 066 (66.13%) adequately participated (those who
had a definitive positive or negative result) and from this 2117
(7.82%) had a FIT result X20 mg g 1, which was classed as
positive. From this group, 1818 (85.88%) had a definitive outcome
recorded, this is a similar proportion of those undergoing further
investigation as reported in other studies (Logan et al, 2011).
Where a diagnostic appointment was made and an individual did
not attend, this was classified as ‘Not attended’ and where an
appointment was cancelled the outcome was classified as
‘Cancelled’ (Supplementary Table S2). Complete cases gave the
final sample of n¼ 1810 after removing eight records without an
IMD score (Figure 1 for Study flow diagram).
Seventy-two cancers, 214 high-risk adenomas, 262 intermediate-
risk adenomas and 466 low-risk adenomas were detected in the
study group. This gave 549 cases with a positive outcome (cancer
and advanced adenomas) and 1261 participants with a negative or
low-risk outcome. The mean age of this group was 66.54 years
(Table 1 for outcome by age and sex). The FIT result ranged from
20 mg g 1 to 20 854 mg g 1 (other studies have reported a similarly
high result (Auge et al, 2014)), with a median result of 55.6 mg g 1.
There were 912 individuals served by the Midlands hub and 898 by
the Southern hub. The FIT concentration increased relative to the
severity of the outcome Supplementary Figure S1.
Logistic regression model (complete cases used for analysis
n¼ 1810). Backwards elimination identified that the FIT result,
sex and previous screening history were significantly associated
with CRC and advanced adenoma (the final logistic regression
model is shown in Table 2). The odds of CRC and advanced
adenoma increase as the FIT result increases (OR: 1.434; CI:
1.309—1.573), for males (OR: 1.749; CI: 1.415–2.166) and for
previous non-responders (OR: 2.271; CI: 1.422–3.667). Age was
found to not be statistically significant but was retained in the
model because of clinical importance (OR: 1.020; CI: 0.889—
2.112). IMD was removed from the model (OR: 0.997; CI: 0.990–
1.004, P¼ 0.457).
Discrimination and calibration. The ROC curves for both
models are presented in Figure 2. The AUC for the FIT only
model was 0.63 (95% CI: 0.60–0.66) compared with 0.66 for the
risk-adjusted model, indicating improved discrimination (95% CI:
0.63–0.69). The AUCs were significantly different (D¼  2.7601,
P-value¼ 0.006).
The calibration plots of observed risk against predicted risk are
given for both models in Supplementary Figure S2. The calibration
for the risk-adjusted model based on the Hosmer–Lemeshow
statistic was 0.898 vs 0.481 for the FIT. Small P-values and points
that are far from the line of equality in the calibration plot indicate
a poor fit.
Test accuracy. Test accuracy is presented in a 2 by 2 table for a
threshold of 160 mg g 1 (Table 3). At all investigated thresholds,
the sensitivity and specificity of risk adjusted FIT was greater than
FIT alone (see Supplementary Table S3). At a threshold of
160 mg g 1 (keeping the referral rate the same gives an equivalent
risk threshold of 0.389 for the risk-adjusted model), the FIT has a
sensitivity of 30.78 vs 33.15% for the risk-adjusted model and a
specificity of 83.66 vs 84.69%.
The risk-adjusted model for this sample population leads to the
detection of 13 additional advanced adenomas and the same
number of cancers (17 more high-risk adenomas, 4 less
intermediate-risk adenomas) when compared with the FIT only
at an equivalent threshold of 160 mg g 1. The severity profiles of
the detected lesions are shown in Table 3 (further thresholds
presented in Supplementary Tables S4–S6).
Presenting the results by sex (Table 4) shows the risk model at
160 mg g 1 recalls more men and fewer women, increases detection
in men but decreases detection in women when compared to the
FIT result alone. The FIT result alone recalled 225 men (115 TP –
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true positives, 110 FP – false positives), of which 115 had cancer or
advanced adenoma (51.11%) and 150 women (54 TP, 96 FP) where
54 (36%) had cancer or advanced adenoma. The logistic regression
model recalled 314 men (156 TP, 158 FP), of which 156 (49.68%)
had cancer or advanced adenoma, and 61 women (26 TP, 35 FP),
of which 26 (42.62%) had cancer or advanced adenoma. Results by
sex are shown at different thresholds in Supplementary Tables S7–
S13. Supplementary Table S14 also gives the cancer and advanced
NHS BCSP FIT Pilot
Average risk screening population 
aged 60–74 years from the ‘Midlands and 
North-West’ and ‘Southern’
Screening Hubs in England.
One in 28 people invited for 
screening were offered a FIT 
(40 930) instead of the currently 
used gFOBT (1 126 087)
FIT Participants identified from data 
extract (those sent a FIT kit)
39 874
Limited to those who adequately 
participated (those with a definitive 
positive/negative result)
27 066
Colonoscopy/
diagnostic testing positive
1019
Cancer (74) 
High risk (214) 
Intermediate risk (263) 
Low risk (468)
(299)
Did not attend colonoscopy or cancelled (298)
Cancelled(where an individual cancelled a 
diagnostic appointment) – (35) 
Not attended (where a diagnostic appointment 
was made but the individual did not attend) -
(263) 
One participant had an abnormal FIT but overall 
outcome was recorded as normal – outcome 
was set as missing.
Colonoscopy/
diagnostic testing negative
799
Normal after diagnostic testing (266) 
Abnormal (other abnormality detected other 
than polyp/cancer e.g. haemorrhoids) (533)
Limited to those with a positive FIT 
result of  20 µg Hb g–1 faeces
2117
Participants with a definitive 
outcome at colonoscopy (n = 1818) 
1056 opted to not be sent a kit 
after being sent a screening 
invite
Sent a FIT kit back
27 154
Participants limited to complete 
cases for analysis (n = 1810) 
Exclude participants
sent a gFOBT 1 118 365
12 720 did not return the FIT kit
Exclude the 88 participants 
who did not obtain a definitive 
result from their FIT kit (i.e. 
positive or negative)
Exclude 24 949 participants 
with a normal test result (less 
than 20 µg g–1)
Exclude 299 (14.12%) 
participants who do not have a 
definitive diagnostic outcome 
because of not attending a 
diagnostic appointment or 
cancelling (84 people were not 
suitable for colonoscopy, 80 
people were unknown and 135 
were suitable for colonoscopy)
Exclude 8 participants who 
have data for IMD score 
missing based on postcode
Figure 1. Study flow diagram.
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adenoma detection rates for each sex and screening history
subgroup.
Neural network. A network with five input nodes, three hidden
layer nodes and one output node gave the lowest cross-validated
deviance (2103.04) and was selected to develop further. A weight
decay of 0.01 gave the smallest SSE (346.0445). The model with the
lowest cross-validated deviance (2077.694) after pruning is shown
graphically in Supplementary Figure S3 and includes the FIT result,
age, sex and previous screening history. Supplementary Figure S4
shows the risk equation for the final neural network and
Supplementary Table S15 gives the corresponding weight connec-
tion values.
The AUC for the neural network was higher than the equivalent
logistic regression model: 0.69 (95% CI: 0.66–0.71). An ROC test
between the logistic regression model and the neural network
shows that the AUC is statistically significantly different
(D¼  3.5057, P-value¼ 0.0005). ROC curves of all three models
are given in Figure 2. Calibration for the neural network gave a
similar result (0.8924) to the logistic regression model (0.8977).
Patient profiles are presented for both the logistic regression and
neural network risk models in Supplementary Table S16.
At all investigated thresholds, the sensitivity and specificity of
the neural network was greater than the equivalent logistic
regression model. For 160 mg g 1 the sensitivity of the neural
network was 35.15% and the specificity 85.57%. Applying the
neural network at a threshold of 160 mg g 1 leads to 24 more
advanced adenomas being detected and the same number of
cancers (30 more high-risk adenomas and 6 less intermediate-risk
adenomas) compared with FIT only (Tables 3 and 4).
Table 1. Diagnostic outcome by age and sex (n¼1810)
Diagnostic outcome Age category, female Age category, male
p60 61–65 66–70 71–75 Total p60 61–65 66–70 71–75 Total
Abnormal 29 90 93 70 282 28 86 85 50 249
Cancer 2 5 6 10 23 4 15 21 10 50
High-risk adenoma 7 12 27 23 69 17 37 58 33 145
Intermediate-risk adenoma 13 23 45 18 99 20 53 52 38 163
Low-risk adenoma 18 67 73 45 203 33 84 90 56 263
Normal (no abnormalities found) 23 45 57 19 144 13 39 36 32 120
Total 92 242 301 185 820 115 314 342 219 990
Table 2. Final multiple logistic regression model (FIT combined with risk indicators)
Coefficients Estimate Std. error Pr (4|z|) OR (95% CI)
Intercept 4.439 0.934 o0.001 0.012 (0.002–0.073)
log(FIT result þ 1) 0.360 0.047 o0.001 1.434 (1.309–1.573)
Age at episode start 0.020 0.015 0.171 1.020 (0.991–1.050)
Sex (male) 0.559 0.109 o0.001 1.749 (1.415–2.166)
First time invitee 0.000 — — —
Previous non-responder (compared wih first time
screen)
0.820 0.241 0.001 2.271 (1.422–3.667)
Previous responder (compared with first time screen) 0.308 0.220 0.162 1.361 (0.889–2.112)
Abbreviations: CI¼ confidence interval; FIT¼ faecal immunochemical test; OR¼odds ratio; Pr¼probability. Risk equation:
P ¼ e
4:44þ0:360x1þ0:02x2þ0:56x3þ0:82x4þ0:31x5
1þe4:44þ0:360x1þ0:02x2þ0:56x3þ0:82x4þ0:31x5
where P is the probability; x1 the log(FIT result þ 1); x2 the age at episode start; x3 the sex (male compared with female at baseline); x4 the previous non-responder (compared with first time
screen); x5 the previous responder (compared with first time screen). Null deviance – 2221.4 on 1809 degrees of freedom; residual deviance – 2103.0 on 1804 degrees of freedom; AIC – 2115;
number of Fisher scoring iterations – 4; Nagelkerke’s R2 – 0.09 (risk-adjusted model) and 0.05 (FIT only); events per variable/parameter – 91.5 (549 events/5 parameters þ 1 for the parameter
representing the constant).
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Figure 2. ROC curves for FIT only compared with the risk-adjusted FIT
and neural network models. Area under the curve (AUC) (95% CI) for
the Neural Network Model: 0.686 (0.659–0.712); AUC (95% CI) for the
Risk-adjusted Logistic Regression Model: 0.659 (0.632–0.686); AUC
(95% CI) for the FIT only: 0.628 (0.600–0.656).
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At 160 mg g 1 compared with the logistic regression model, the
neural network increases the number of cancers and advanced
adenomas detected for women equalising the difference seen
between the sexes and also halves the number of FP results for
women compared with FIT only. The neural network recalled 279
men (146 TP, 133 FP), of which 146 (52.33%) had cancer or
advanced adenoma, and 96 women (47 TP, 49 FP), of which 47
(48.96%) had cancer or advanced adenoma. The neural network
improves the percentage of cancers/advanced adenomas detected
in those recalled for further diagnostic tests (PPV – positive
predictive value).
DISCUSSION
This study has demonstrated that including routinely available risk
predictors in the screening algorithm alongside the FIT can
improve both model performance and test accuracy. The risk-
adjusted screening algorithm detected 13 more advanced adeno-
mas and the same number of cancers when keeping the referral
rate constant at a FIT threshold of 160 mg Hb g 1 faeces. Based on
the results from this data, for every 1 000 000 people invited to
screening, we estimate 318 additional advanced adenomas (4447/
1 000 000) would be detected compared with FIT only (4129/
1 000 000). Although this approach would require external
validation, the figures give the relative performance of this risk-
based approach. The algorithm mainly improves detection in men
compared with women.
By extending the model using more complex methods, the
neural network was shown to improve model performance and test
accuracy further with the detection of 24 more advanced adenomas
(FIT threshold 160 mg g 1). For every 1 000 000 people invited to
screening, we estimate 586 additional advanced adenomas would
be detected compared with FIT (4715/1 000 000). This modelling
approach also equalised the difference in cancers/advanced
adenomas detected between men and women seen with the logistic
regression model. Although the neural network recalls fewer
women, the PPV is increased compared with the other models and
is similar between the sexes (men – 52.33; women – 48.96%).
Strengths of the study include the quality of data since this was
collected for the FIT pilot comparative study, which was
implemented within a live screening programme. In addition,
routine data were used to develop the risk prediction model
meaning no additional data collection, reducing costs and the
burden on screening participants. The test thresholds analysed
were those that were identified in the FIT pilot as well as other
internationally used thresholds to aid comparison of a risk-
adjusted approach.
Limitations of the study include the lack of follow-up data for
participants with a result of o20 mg g 1. Ideally, follow-up data
for participants sent the FIT would be obtained from cancer
registries (National Cancer Intelligence Network, or Office for
National Statistics data). A follow-up period of 2 years would allow
the clinical identification of existing cancers. Not all individuals
had a diagnostic result if they cancelled or did not attend the
appointment and this could cause potential selection bias if non-
healthy participants tend to not have follow-up colonoscopy. The
pattern of attendance for diagnostic investigation seen in this study
is, however, similar to that seen in the screening programme in
general (Logan et al, 2011). By selecting those with a result of
X20 mg g 1 and limiting to those with a definitive diagnostic
outcome, the selected groups are at higher risk of CRC than the
general screening population. This approach can lead to partial
verification bias and inflated test accuracy measures (de Groot
et al, 2011; Naaktgeboren et al, 2016). However, the results
provided in this study give relative performance of a risk-adjusted
approach vs a regular screening approach.
Part of the increase in detection for the FIT in the pilot was due
to increased uptake of this test compared with the gFOBT (66.4 vs
59.3%) (Moss et al, 2015); this study assumes the same uptake seen
with the pilot. In subsequent FIT screening rounds, there could be
a change in the uptake whereby non-responders to gFOBT are
more likely to respond to the FIT, whereas non-responders to FIT
may be less likely to respond to the next FIT. This could affect
future detection rates and subsequently model performance.
However, data from four rounds of a biennial FIT screening
programme in the Netherlands showed that uptake increased from
60 to 63%, and the same could be expected with this new test (van
der Vlugt et al, 2017).
Table 3. Two by two table for FIT only, the risk-adjusted logistic regression model and the neural network
Diagnostic positive Diagnostic negative Total
160lg Hbg 1
faeces
threshold FIT Risk-adjusted
Neural
network FIT Risk-adjusted Neural network
FIT/risk positive 169
37 – Cancer
66 – High-risk
adenoma
66 –
Intermediate-risk
adenoma
182
37 – Cancer
83– High-risk
adenoma
62 –
Intermediate-risk
adenoma
193
37 – Cancer
96 – High-risk
adenoma
60 –
Intermediate-risk
adenoma
206
70 – Abnormal
92 – Low-risk
adenoma
44 – Normal (no
abnormalities found)
193
69 – Abnormal
81 – Low-risk
adenoma
43 – Normal (no
abnormalities found)
182
62 – Abnormal
79 – Low-risk
adenoma
41 – Normal (no
abnormalities found)
375
FIT/risk negative 380
36 – Cancer
148 – High-risk
adenoma
196 –
Intermediate-risk
adenoma
367
36 – Cancer
131 – High-risk
adenoma
200 –
Intermediate-risk
adenoma
356
36 – Cancer
118 – High-risk
adenoma
202 –
Intermediate-risk
adenoma
1055
396 – Abnormal
439 – Low-risk
adenoma
220 – Normal (no
abnormalities found)
1068
397 – Abnormal
450 – Low-risk
adenoma
221 – Normal (no
abnormalities found)
1079
404 – Abnormal
452 – Low-risk
adenoma
223 – Normal (no
abnormalities found)
1435
Total 549 1261 1810
Abbreviations: FIT¼ faecal immunochemical test; Hb¼haemoglobin. A threshold of 160mg Hbg 1 faeces was used for the FIT, which is equivalent to a risk threshold of 0.389 for the risk-
adjusted model and 0.407 for the neural network. Profiles of outcome severity are also given. FIT only: Sensitivity 30.78%, specificity 83.66%, PPV 45.07%, NPV 73.52%, FIT positivity 20.72%,
cancer detection rate 9.34%. Risk adjusted: Sensitivity 33.15%, specificity 84.69%, PPV 48.53%, NPV 74.42%, FIT positivity 20.72%, cancer detection rate 10.60%. Neural network: Sensitivity
35.15%, specificity 85.57%, PPV 51.47%, NPV 75.19%, FIT positivity 20.72%, cancer detection rate 10.66%.
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Other studies that have investigated the added value of risk
factors combined with the FIT include a study in the Netherlands,
which combined the following risk predictors: total calcium intake,
family history, age and FIT result (OC-Sensor) (Stegeman et al,
2014). The AUC ROC improved from 0.69 to 0.76 compared with
an improvement of 0.63 to 0.66 reported in this research. This
study obtained its additional data using a questionnaire, which
would rely on a response with a potential negative impact on
uptake, whereas our study used routine data.
Stratification of risk using a logistic regression model combining
age and sex with the FIT result has been investigated by Auge et al
(2014). CRC risk was stratified into 16 categories and 3 risk levels
based on the positive predictive value. The authors suggest that this
stratified approach could be used to prioritise higher risk
individuals for colonoscopy. By categorising risk, however, we
lose individual information as the probabilities become standar-
dised for all individuals in one group (Moons et al, 2015). Our
study gives an absolute risk prediction for each individual,
providing a personalised and potentially more accurate approach
to screening.
This study utilised the data recorded routinely on the BCSS to
develop a risk prediction model, which could be implemented in
practice without additional data collection. Although the perfor-
mance of the neural network was better than the logistic regression
model, the interpretation of neural networks is more complex and
for this reason they are not routinely used in clinical practice
(Dayhoff and DeLeo, 2001; Sargent, 2001). Both models, on the
other hand, give the absolute risk prediction for each individual
and this can be used to make clinical decisions regarding screening
referral by setting an appropriate ‘risk threshold’. In addition, if
further predictors are investigated in the future, nonlinear
predictors and model interactions may be better captured with a
neural network or other machine-learning algorithm.
Based on the results of this study, a risk-adjusted approach
could be implemented at the point of screening to decide which
participants are at greatest risk for more targeted colonoscopy
referral. Before application of a risk-adjusted approach, external
validation of the model would be required to assess performance
also enabling a more accurate risk positivity threshold to be
derived. The algorithm led to greater detection in males compared
to females, which depending on screening programme aims will
need greater investigation (e.g. using separate models for each sex).
Likewise, the detection rate seen between responders/non-
responders/first-time invitees will need consideration in future
risk models by dissecting previous screening history in greater
detail.
Model performance metrics including Nagelkerke’s R2, AUC
and the deviance suggest that the prediction of cancer/advanced
adenomas at colonoscopy is not fully explained or captured by
predictors used in the model. Future research should therefore
focus on the investigation of additional predictors from the BCSS
to improve predictive performance. Additional predictors from the
BCSS could include flexible sigmoidoscopy participation and
previous colonoscopy results, the outcomes of which affect future
risk. Previous FIT results could also be monitored over time as the
Hb concentration relates to the detection of adenomas in future
screening rounds (Digby et al, 2016). Spot positivity of previous
gFOBTs could also be investigated while transitioning over to the
FIT (Geraghty et al, 2014). Lifestyle factors have also been shown
to have a significant effect on the risk of CRC (diet, alcohol,
physical inactivity and being overweight) (Parkin et al, 2011).
Although this information is not currently included on the BCSS,
other sources such as electronic health records or questionnaires
could be used to obtain this information.
As the NHS BCSP prepares to transition to the FIT in 2018, these
initial investigations have shown that further exploration of the BCSS
for additional predictors which could be included in the screening
algorithm may help to improve test accuracy and make more effective
use of an expensive and severely limited colonoscopy resource.
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Table 4. Two by two table for FIT only, the risk-adjusted logistic regression model and the neural network split by sex
Diagnostic positive Diagnostic negative
FIT only Risk-adjusted Neural network FIT only Risk-adjusted Neural network Total
160 lg Hb g 1
faeces threshold Male Female Male Female Male Female Male Female Male Female Male Female
FIT/risk positive Total 115 54 156 26 146 47 Total 110 96 158 35 133 49
Cancer 27 10 29 8 27 10 Low-risk adenoma 41 29 60 9 49 13
High-risk adenoma 45 21 72 11 71 25 Abnormal 51 41 66 15 59 20 375
Intermediate-risk
adenoma
43 23 55 7 48 12 Normal (no
abnormalities found)
18 26 32 11 25 16
FIT/risk negative Total 243 137 202 165 212 144 Total 522 533 474 594 499 580
Cancer 23 13 21 15 23 13 Low-risk adenoma 222 174 203 194 214 190
High risk adenoma 100 48 73 58 74 44 Abnormal 198 241 183 267 190 262 1435
Intermediate risk
adenoma
120 76 108 92 115 87 Normal (no
abnormalities found)
102 118 88 133 95 128
Total 549 1261 1810
Abbreviations: FIT¼ faecal immunochemical test; Hb¼haemoglobin. A threshold of 160mg Hbg 1 faeces was used for the FIT, which is equivalent to a risk threshold of 0.389 for the risk-
adjusted model and 0.407 for the neural network. Profiles of outcome severity are also given.
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